30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting
plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in
patients with type 2 diabetes mellitus (T2DM) with inadequate glycemic control.